The UHLG Breast research team are proud to celebrate the outstanding dedication and hard work within research.
The team has exceeded recruitment targets across all studies and remain one of the top recruiting teams nationally—a truly remarkable and ongoing achievement.
To take part in a research study please contact the team.
A double-blinded study to evaluate how effective lidocaine infusions are to treat chronic post-surgical pain (CPSP), when given during surgery and extending up to 24 hours post-surgery, in those who are undergoing breast cancer surgery
This trial is for patients aged 18 and over who are undergoing a mastectomy or breast conserving surgery (one or both breasts), for the primary excision of confirmed or suspected breast cancer under general anaesthesia
Improving outcomeS for Women diagnosed with early breast cancer through adhErence to adjuvant Endocrine Therapy.
The aim of this trial is to determine the clinical effectiveness of the HT&Me app in reducing poor adherence to hormone therapy (ET) and improving cancer specific health-related quality of life.
For patients recently diagnosed with ER-positive invasive breast cancer (stages 1-3) who are being treated with curative intent and who have been prescribed oral adjuvant ET within the past 14 weeks
Women who have finished chemotherapy but still receiving radiotherapy are still eligible.
Open Surgery versus Minimally invasive vacuum-Assisted excision for smaLL screen-detected breast Cancer.
This trial aims to determine whether the extent of surgical treatment for early screen-detected biologically favourable breast cancer can be reduced.
- Women aged 47 and over
- <15mm maximum tumour diameter on screen-detected mammogram and ultrasound
- No associated malignant microcalcification outwith the mass lesion (within is permitted)
This trial is to see how best to support women with breast cancer in taking their medication by testing combinations of four different interventions. Some people may receive a combination of interventions, one intervention or no interventions.
For patients aged 18 and older with early stage (1-3) breast cancer (including those being treated for a second primary or local recurrence) treated with curative intent.
Reducing ethnic inequalities for Black women with breast cancer: the role of treatment uptake, engagement and support.
This trial explore how societal or health system factors impact on someone’s motivation and ability to engage with their ET treatment, and whether key predictors of adherence may differ in different ethnic groups.
Understanding side effects experienced by women prescribed hormone therapy.
This trial aims to investigate the influence of AET brand changes on adherence and AEs in those patients’ receiving treatment for breast cancer.
